Scopus İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/11727/4809

Browse

Filters

2016 - 20202

Settings

search.filters.applied.f.publicationcategory: search.filters.publicationcategory.Makale - Uluslararası Hakemli DergiSubject: search.filters.subject.choroidal thickness

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Evaluation of Iridocorneal Angle, Choroidal Thickness, and Retinal Nerve Fiber Layer Thickness in Children With a History of Retinopathy of Prematurity
    (2020) Ulusoy, Mahmut Oguz; Kivanc, Sertac Argun; Kal, Ali; 31790064
    Purpose: Retinopathy of prematurity (ROP) is proliferative retinopathy affecting premature infants associated with abnormal maturation of the retinal vasculature. We sought to evaluate iridocorneal angle, choroidal thickness, and retinal nerve fiber layer thickness (RNFLT) of the children that have a history of ROP using spectral-domain optical coherence tomography. Patients and Methods: Fifty eyes of 28 children with a history of ROP and 46 eyes of 23 healthy school-aged children were included in this study. RNFLT, choroidal thickness, and iridocorneal angle parameters [trabecular iris angle, angle opening distance (AOD500), and trabecular iris space area (TISA500) 500 mu m from the scleral spur] were evaluated using spectral-domain optical coherence tomography. Student t test was used to compare the mean of the parameters. Correlations between the variables were investigated based on the Pearson or Spearman correlation coefficient. Results: Subfoveal (ROP: 253.98 +/- 42.5; control: 286.2 +/- 71.9; P=0.045), 500 mu m (ROP: 242.04 +/- 41.8; control: 276.7 +/- 45.3; P=0.003), 1000 mu m (ROP: 237 +/- 39.7; control: 270.15 +/- 55.93; P=0.007), and 1500 mu m (ROP: 224.16 +/- 37.5; control: 259.75 +/- 55.2; P=0.003) temporal choroidal thicknesses were significantly thinner in ROP history children. None of the RNFLT parameters and ganglion cell complex thickness were different between groups. Iridocorneal angle parameters were significantly lower in children with ROP history. (trabecular iris angle: ROP=31.35 +/- 3.9 degrees, control=35.4 +/- 4.5 degrees, P<0.001; TISA500: ROP=0.167 +/- 0.05 mm(2), control=0.21 +/- 0.05 mm(2), P=0.003; AOD500: ROP=480.96 +/- 160.4 mu m, control=542.95 +/- 161.2 mu m, P=0.035). Conclusions: ROP is associated with differences in the iridocorneal angle. Possible iridocorneal angle pathology should be a consideration in children with a history of ROP.
  • Thumbnail Image
    Item
    Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion
    (2016) Coban-Karatas, Muge; Altan-Yaycioglu, Rana; Ulas, Burak; Sizmaz, Selcuk; Canan, Handan; Sarıtürk, Cagla; 27275430
    AIM: To evaluate central macular thickness (CMT) and mean choroidal thickness (MCT) in eyes with branch retinal vein occlusion (BRVO), before and after ranibizumab treatment using spectral domain -optical coherence tomography (SD-OCT). METHODS: Forty -two patients with unilateral BRVO and macular edema were included in this study. There were 25 men and 17 women. Using SD-OCT, choroidal thickness was measured at 500 mu m intervals up to 1500 mu m temporal and nasal to the fovea. MCT was calculated based on the average of the 7 locations. All the eyes with BRVO were treated with intravitreal ranibizumab (0.5 mg/0.05 mL). Comparisons between the BRVO and fellow eyes were analyzed using Mann-Whitney test. Pre-injection and post-injection measurements were analyzed using Wilcoxon test and repeated measure analysis. RESULTS: At baseline, there was a significant difference between the BRVO and fellow eyes in MCT [BRVO eyes 245 (165-330) mu m, fellow eyes 229 (157-327) mu m] and CMT [BRVO eyes 463 (266-899) mu m, fellow eyes 235 (148-378) mu m (P=0.041, 0.0001, respectively)]. Following treatment, CMT [295 (141-558) mu m] and MCT [229 (157329) mu m] decreased significantly compared to the baseline measurements (P=0.001, 0.006, respectively). Also BCVA (logMAR) improved significantly (P=0.0001) in the BRVO eyes following treatment. After treatment CMT [BRVO eyes 295 (141-558) mu m, fellow eyes 234 (157-351) mu m] and MCT [BRVO eyes 229 (157-329) mu m, fellow eyes 233 (162-286) mu m] values did not reveal any significant difference in BRVO eyes and fellow eyes (P=0.051, 0.824, respectively). CONCLUSION: In eyes with BRVO, CMT and MCT values are greater than the fellow eyes, and decrease significantly following ranibizumab injection.